Sarepta secured a broad release for products using the AAVrh74 capsid, including ELEVIDYS, removing the patent overhang while paying $39.0 million already recorded as a charge.
The settlement ends pending patent fights over the AAVrh74 capsid used in ELEVIDYS and brings legal certainty for Sarepta. Sarepta will pay $39.0 million, an amount it already charged, so the cash hit is modest versus the gain in cleared risk.
REGENXBIO will receive $39.0 million but gave up the right to sue over patents covering the AAVrh74 capsid and the existing form of ELEVIDYS, reducing future enforcement leverage.
Follow Sarepta Therapeutics, Inc. (SRPT) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for SRPT